絞り込み

16535

広告

Bone metabolism in Langerhans cell histiocytosis.

著者 Anastasilakis AD , Tsoli M , Kaltsas GA , Makras P
Endocr Connect.2018 Jul 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (28view , 0users)

Full Text Sources

Langerhans Cell histiocytosis (LCH) is a rare disease of not well-defined aetiology that involves immune cell activation and frequently affects the skeleton lacking a targeted therapeutic approach. Bone involvement in LCH usually presents in the form of osteolytic lesions along with low bone mineral density. Various molecules involved in bone metabolism are implicated in the pathogenesis of LCH or may be affected during the course of the disease, including interleukins (ILs), tumor necrosis factor α, receptor activator of NF-kB (RANK) and its soluble ligand RANKL, osteoprotegerin (OPG), periostin and sclerostin. Among them IL-17A, periostin and RANKL have been proposed as potential serum biomarkers for LCH, particularly as the interaction between RANK, RANKL, and OPG not only regulates bone homeostasis through its effects on the osteoclasts but also affects the activation and survival of immune cells. Significant changes in circulating and lesional RANKL levels have been observed in LCH patients irrespective of bone involvement. Standard LCH management includes local or systematic administration of corticosteroids, and chemotherapy. Given the implication of RANK, RANKL, and OPG in the pathogenesis of the disease and the osteolytic nature of bone lesions, agents aiming at inhibiting the RANKL pathway and/or osteoclastic activation, such as bisphosphonates and denosumab, may have a role in the therapeutic approach of LCH although further clinical investigation is warranted.
PMID: 29967185 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード